Prescription Drug Spending Remains Low, As Generics Continue To Dominate -Medco
This article was originally published in The Pink Sheet Daily
Executive Summary
OTC entries drive Rx utilization down.
You may also be interested in...
Oncology Drug Spending By Health Plans May Rise 50% By 2010 – Medco
Long-term cancer treatment with targeted oral therapies will spur a 46 percent to 53 percent surge in health plan spending on oncology drugs within the next three years, Medco predicts in its 2008 Drug Trend Report (see chart: "1Drug Spending By Health Plans: 2008-2010 Forecast")
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.
Affymax's Share Price Stumbles On Questionable Phase III Hematide Data
Phase III data for Affymax/Takeda's anemia drug for chronic kidney failure signals potential regulatory hurdles in non-dialysis use.